<DOC>
	<DOCNO>NCT02006472</DOCNO>
	<brief_summary>This multicenter , multinational , randomize , parallel-group , double-blind , placebo-controlled , range find study compare efficacy safety different dos pridopidine versus placebo treatment motor impairment Huntington 's Disease ( HD ) .</brief_summary>
	<brief_title>A Phase 2 , Evaluating Safety Efficacy Pridopidine Versus Placebo Symptomatic Treatment Patients With Huntington 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Diagnosis HD base presence &gt; /= 36 CAG repeat Male female age ≥21 year , onset HD 18 year ' old . Females child bear potential compliant use adequate birth control throughout duration study Body weight ≥50 kg Sum &gt; /= 25 point UHDRSTMS UHDRS Independence Score 90 % Able willing provide write informed consent prior study related procedure . Willing provide blood sample genetic analysis Willing able take oral medication able comply study specific procedure . Ambulatory , able travel study centre , judge investigator likely able continue travel duration study . Availability willingness caregiver , informant family member accompany patient clinic study , suitability caregiver judge investigator . Other criterion apply , please contact investigator information . Patients clinically significant heart disease screen visit Treatment tetrabenazine within 6 week study screen Patients history epilepsy seizure within last 5 year Have serious medical illness opinion investigator may put patient risk participate study may influence result study affect patient 's ability take part study Patients receive medication ( within last 6 week prior screen ) proven prolong QT interval may require medication course study limit non allow anti psychotic medication , tricyclic antidepressant and/or Class I antiarrhythmics Patients receive medication ( within last 6 week prior screen ) metabolize CYP2D6 potential reducing seizure threshold Other criterion apply , please contact investigator information</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Huntington 's Disease</keyword>
	<keyword>Pridopidine</keyword>
	<keyword>Pride-HD</keyword>
</DOC>